About This Reference Desk

What Peptide Friend is

Peptide Friend is an independent editorial reference desk covering the published research on three peptides that appear frequently in conversations about cognition, mood, anxiety and sleep: Semax, Selank, and DSIP, with Selank as the lead compound. The site exists to make a scattered, often geographically concentrated, and frequently overstated literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence reaches.

The organizing approach is an honest three-way comparison. Selank has the most direct human clinical data among the three (a small Russian generalized-anxiety trial). Semax has the deepest rodent mechanistic record and a prescription registration in Russia. DSIP has the longest history and the weakest mechanistic resolution, with a 2006 mainstream review describing its sleep evidence as extremely poorly documented. Each compound gets its own page; a comparison page lines them up; and a shared references list aggregates every source cited across the site.

Community-reported experiences — what people in nootropic forums and peptide communities say they observe — are included on the per-compound pages where the source material contains them, clearly labeled as anecdotal and kept separate from the cited research findings. That distinction is not a formality. It is the substance of what this site offers: knowing where the clinical record stops and community experience begins.

How it is compiled

Three principles govern what appears here.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — journal articles and reviews indexed in PubMed or equivalent databases, with DOIs or PubMed links — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as a review.

Second, the evidence is described at its actual strength. Doses are reported the way studies state them: studied at 50 micrograms per kilogram in rats, or in six chronic insomniacs in a 1981 pilot trial. Where evidence is preclinical, single-lab, from a single geographic tradition, or rests on analogs rather than the marketed compound, the page says so. Candor about limits is not a hedge — it is the accurate description of the record.

Third, the three pages are cross-referenced. The same themes — neurotrophin signaling, GABA modulation, enkephalinase inhibition, neuroendocrine effects — recur across compounds, and the pages link to one another so a reader can trace a mechanism from one peptide to the next.

What it is not

Peptide Friend is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never presents an animal-study dose as something a human should take.

The peptides discussed here are research compounds. None is an approved medicine for human use in the United States or European Union. Two are registered prescription drugs in Russia only — which means something for their clinical history but does not constitute FDA or EMA approval. One has no approved therapeutic registration anywhere. Readers interested in any condition described in the underlying research — anxiety, sleep disorders, cognitive impairment — should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options. The value this site offers is a calm, accurate map of the literature — not more, and not pretending to be.